Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oncotarget ; 7(38): 61930-61944, 2016 Sep 20.
Article in English | MEDLINE | ID: mdl-27542280

ABSTRACT

Tn antigen (GalNAc-α-O-Ser/Thr), a mucin-type O-linked glycan, is a well-established cell surface marker for tumors and its elevated levels have been correlated with cancer progression and prognosis. There are also reports that Tn is elevated in inflammatory tissues. However, the molecular mechanism for its elevated levels in cancer and inflammation is unclear. In the current studies, we have explored the possibility that cytokines may be one of the common regulatory molecules for elevated Tn levels in both cancer and inflammation. We showed that the Tn level is elevated by the conditioned media of HrasG12V-transformed-BEAS-2B cells. Similarly, the conditioned media obtained from LPS-stimulated monocytes also elevated Tn levels in primary human gingival fibroblasts, suggesting the involvement of cytokines and/or other soluble factors. Indeed, purified inflammatory cytokines such as TNF-α and IL-6 up-regulated Tn levels in gingival fibroblasts. Furthermore, TNF-α was shown to down-regulate the COSMC gene as evidenced by reduced levels of the COSMC mRNA and protein, as well as hypermethylation of the CpG islands of the COSMC gene promoter. Since Cosmc, a chaperone for T-synthase, is known to negatively regulate Tn levels, our results suggest elevated Tn levels in cancer and inflammation may be commonly regulated by the cytokine-Cosmc signaling axis.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate/metabolism , Gene Expression Regulation, Neoplastic , Interleukin-6/metabolism , Molecular Chaperones/metabolism , Tumor Necrosis Factor-alpha/metabolism , Breast Neoplasms/immunology , Breast Neoplasms/metabolism , Bronchi/metabolism , Cell Line , CpG Islands , Culture Media, Conditioned , DNA Methylation , Disease Progression , Female , Fibroblasts/metabolism , Genes, ras , Gingiva/cytology , Humans , Inflammation , Male , Prognosis , Promoter Regions, Genetic , Prostatic Neoplasms/immunology , Prostatic Neoplasms/metabolism , Signal Transduction , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/metabolism
2.
PLoS One ; 9(12): e111529, 2014.
Article in English | MEDLINE | ID: mdl-25486007

ABSTRACT

Low HDL-C levels are associated with atherosclerosis and non-alcoholic steatohepatitis, and increased levels may reduce the risk of these diseases. Inhibition of cholesteryl ester transfer protein (CETP) activity is considered a promising strategy for increasing HDL-C levels. Since CETP is a self-antigen with low immunogenicity, we developed a novel CETP vaccine (Fc-CETP6) to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity. The vaccine consists of a rabbit IgG Fc domain for antigen delivery to antigen-presenting cells fused to a linear array of 6 repeats of a CETP epitope to efficiently activate B cells. Rabbits were fed a high fat/cholesterol (HFC) diet to induce atherosclerosis and NASH, and immunized with Fc-CETP6 vaccine. The Fc-CETP6 vaccine successfully elicited anti-CETP antibodies and lowered plasma CETP activity. The levels of plasma HDL-C and ApoA-I were higher, and plasma ox-LDL lower, in the Fc-CETP6-immunized rabbits as compared to the unimmunized HFC diet-fed rabbits. Pathological analyses revealed less lipid accumulation and inflammation in the aorta and liver of the Fc-CETP6-immunized rabbits. These results show that the Fc-CETP6 vaccine efficiently elicited antibodies against CETP and reduced susceptibility to both atherosclerosis and steatohepatitis induced by the HFC diet. Our findings suggest that the Fc-CETP6 vaccine may improve atherosclerosis and NASH and has high potential for clinical use.


Subject(s)
Atherosclerosis/etiology , Atherosclerosis/prevention & control , Cholesterol Ester Transfer Proteins/immunology , Diet, High-Fat/adverse effects , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/prevention & control , Vaccines/immunology , Animals , Antibodies/blood , Antibodies/immunology , Apolipoprotein A-I/metabolism , Atherosclerosis/pathology , Cholesterol/blood , Cholesterol/metabolism , Cholesterol Ester Transfer Proteins/genetics , Cholesterol Ester Transfer Proteins/metabolism , Disease Models, Animal , Female , Fibrosis , Gene Expression , Humans , Immunoglobulin Fc Fragments/genetics , Immunoglobulin Fc Fragments/immunology , Lipoproteins, LDL/metabolism , Non-alcoholic Fatty Liver Disease/pathology , Rabbits , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Vaccines/genetics
3.
Dev Cell ; 28(4): 409-22, 2014 Feb 24.
Article in English | MEDLINE | ID: mdl-24576425

ABSTRACT

Erythropoiesis is a highly regulated process during which BFU-E are differentiated into RBCs through CFU-E, Pro-E, PolyCh-E, OrthoCh-E, and reticulocyte stages. Uniquely, most erythroid-specific genes are activated during the Pro-E to Baso-E transition. We show that a wave of nuclear import of the erythroid-specific transcription factor EKLF occurs during the Pro-E to Baso-E transition. We further demonstrate that this wave results from a series of finely tuned events, including timed activation of PKCθ, phosphorylation of EKLF at S68 by P-PKCθ(S676), and sumoylation of EKLF at K74. The latter EKLF modifications modulate its interactions with a cytoplasmic ankyrin-repeat-protein FOE and importinß1, respectively. The role of FOE in the control of EKLF nuclear import is further supported by analysis of the subcellular distribution patterns of EKLF in FOE-knockout mice. This study reveals the regulatory mechanisms of the nuclear import of EKLF, which may also be utilized in the nuclear import of other factors.


Subject(s)
Active Transport, Cell Nucleus/genetics , Carrier Proteins/metabolism , Erythropoiesis , Kruppel-Like Transcription Factors/genetics , Protein Kinase C/metabolism , Animals , Cell Differentiation/genetics , DNA-Binding Proteins/genetics , Erythropoiesis/genetics , Gene Expression Regulation, Developmental/genetics , Gene Expression Regulation, Developmental/physiology , Mice , Mice, Knockout , Time Factors
4.
Mol Med Rep ; 5(1): 17-21, 2012 01.
Article in English | MEDLINE | ID: mdl-21971708

ABSTRACT

Membrane-cytoskeleton linker organizer ezrin is a member of the ERM (ezrin-radixin-moesin) protein family. It has been suggested as an important element in the oncogenic process, particularly in conferring a metastatic ability on tumor cells. We hypothesized that the KIT oncogenic form is one of the proteins that modulates expression of the ezrin protein via phosphorylated ezrin at different residues; furthermore, it may interact with the protein merlin, and promoting tumor development via the PI3K or MAPK pathway. In the present study, we observed that differential expression of ezrin was a common feature in gastrointestinal stromal tumors (GISTs). We further demonstrated that cases exhibiting expression of phosphorylated Thr567 in the ezrin protein were associated with immunoactivities of KIT and merlin expression (p=0.039 and 0.013, respectively). In conclusion, GISTs harbor activation of KIT protein may induce phosphorylation of the downstream protein ezrin at certain residues, thereby triggering subsequent signal transduction cascades and driving downstream pathways of tumor progression. However, a larger series of tumor samples should be analyzed in future studies, as well as the identification of phosphorylated sites to determine the role of ezrin in tumor progression thus shedding light on clinical outcomes.


Subject(s)
Cytoskeletal Proteins/metabolism , Gastrointestinal Stromal Tumors/metabolism , Gene Expression Regulation, Neoplastic , Neurofibromin 2/metabolism , Proto-Oncogene Proteins c-kit/genetics , Proto-Oncogene Proteins c-kit/metabolism , Cell Line , Gastrointestinal Stromal Tumors/pathology , Humans , MAP Kinase Signaling System , Mutation , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation
SELECTION OF CITATIONS
SEARCH DETAIL
...